imclone systems inc pharmaceuticals trio plans to market erbitux in japan imclone systems inc and bristol myers squibb co signed an agreement with german drug company merck kgaa to develop and commercialize cancer treatment erbitux in japan if japanese regulators give approval the companies will market erbitux there to treat a specific form of colorectal cancer and possibly other cancers the companies said merck will receive of the profit or loss from sales in japan imclone systems and bristol myers both of new york will receive each in addition imclone will receive from merck a royalty of of the total net sales in japan 
